There’s limited evidence to back up the widespread and increasing rates of prescribing mood-altering drugs (psychotropics) as the mainstay of mental health treatment for children and young people, warn experts in an editorial, published in the August issue of Drug and Therapeutics Bulletin (dtb)
FDA OKs First Interchangeable Biosimilars for Denosumab
The FDA approved injectable Jubbonti and Wyost as the first interchangeable biosimilars to denosumab (Prolia, Xgeva), and for all the same indications, including the prevention
March 7, 2024